Find information on thousands of medical conditions and prescription drugs.

Diabetic neuropathy

Diabetic neuropathies are neuropathic disorders that are associated with diabetes mellitus. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (vasa nervorum). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy; mononeuropathy; mononeuropathy multiplex; diabetic amyotrophy; a painful polyneuropathy; autonomic neuropathy; and thoracoabdominal neuropathy. more...

Dandy-Walker syndrome
Darier's disease
Demyelinating disease
Dengue fever
Dental fluorosis
Dentinogenesis imperfecta
Depersonalization disorder
Dermatitis herpetiformis
Dermatographic urticaria
Desmoplastic small round...
Diabetes insipidus
Diabetes mellitus
Diabetes, insulin dependent
Diabetic angiopathy
Diabetic nephropathy
Diabetic neuropathy
Diamond Blackfan disease
Diastrophic dysplasia
Dibasic aminoaciduria 2
DiGeorge syndrome
Dilated cardiomyopathy
Dissociative amnesia
Dissociative fugue
Dissociative identity...
Dk phocomelia syndrome
Double outlet right...
Downs Syndrome
Duane syndrome
Dubin-Johnson syndrome
Dubowitz syndrome
Duchenne muscular dystrophy
Dupuytren's contracture
Dyskeratosis congenita
Dysplastic nevus syndrome


Diabetes is the leading cause of neuropathy in developed countries, and neuropathy is the most common complication and greatest source of morbidity and mortality in diabetes patients. It is estimated that the prevalence of neuropathy in diabetes patients is approximately 20%. Diabetic neuropathy is implicated in 50-75% of nontraumatic amputations.

The main risk factor for diabetic neuropathy is hyperglycemia. In the DCCT (Diabetes Control and Complications Trial, 1995) study, the annual incidence of neuropathy was 2% per year, but dropped to 0.56% with intensive treatment of Type 1 diabetics. The progression of neuropathy is dependent on the degree of glycemic control in both Type 1 and Type 2 diabetes. Duration of diabetes, age, cigarette smoking, hypertension, height and hyperlipidemia are also risk factors for diabetic neuropathy.

Pathology and pathogenesis

There are four factor involved in the development of diabetic neuropathy:

  1. Microvascular disease,
  2. Advanced glycated end products,
  3. Protein kinase C, and the
  4. Polyol pathway.

Microvascular disease

Vascular and neural diseases are closely related and intertwined. Blood vessels depend on normal nerve function, and nerves depend on adequate blood flow. The first pathological change in the microvasculature is vasoconstriction. As the disease progresses, neuronal dysfunction correlates closely with the development of vascular abnormalities, such as capillary basement membrane thickening and endothelial hyperplasia, which contribute to diminished oxygen tension and hypoxia. Neuronal ischemia is a well-established characteristic of diabetic neuropathy. Vasodilator agents (e.g., angiotensin-converting-enzyme inhibitors, α1-antagonists) can lead to substantial improvements in neuronal blood flow, with corresponding improvements in nerve conduction velocities. Thus, microvascular dysfunction occurs early in diabetes, parallels the progression of neural dysfunction, and may be sufficient to support the severity of structural, functional, and clinical changes observed in diabetic neuropathy.

Advanced glycated end products

Elevated intracellular levels of glucose cause a non-enzymatic covalent bonding with proteins, which alters their structure and destroys their function. Certain of these glycated proteins are implicated in the pathology of diabetic neuropathy and other long term complications of diabetes.

Protein kinase C (PKC)

PKC is implicated in the pathology of diabetic neuropathy. Increased levels of glucose cause an increase in intracellular diacylglycerol, which activates PKC. PKC inhibitors in animal models will increase nerve conduction velocity by increasing neuronal blood flow.


[List your site here Free!]

Evaluation and prevention of diabetic neuropathy
From American Family Physician, 6/1/05 by Ann M. Aring

Diabetic neuropathy is a debilitating disorder that occurs in nearly 50 percent of patients with diabetes. It is a late finding in type 1 diabetes but can be an early finding in type 2 diabetes. The primary types of diabetic neuropathy are sensorimotor and autonomic. Patients may present with only one type of diabetic neuropathy or may develop combinations of neuropathies (e.g., distal symmetric polyneuropathy and autonomic neuropathy). Distal symmetric polyneuropathy is the most common form of diabetic neuropathy. Diabetic neuropathy also can cause motor deficits, silent cardiac ischemia, orthostatic hypotension, vasomotor instability, hyperhidrosis, gastroparesis, bladder dysfunction, and sexual dysfunction. Strict glycemic control and good daily foot care are key to preventing complications of diabetic neuropathy.


Diabetic neuropathy can affect any part of the nervous system. This nerve disorder should be suspected in all patients with type 2 diabetes and in patients who have had type 1 diabetes for more than five years. (1-4) In some instances, patients with diabetic neuropathy have few complaints, but their physical examination reveals mild to moderately severe sensory loss. (2,5) Idiopathic neuropathy has been found to precede the onset of type 2 diabetes or to occur as an early finding in the disease. (2-5)

Classification of Diabetic Neuropathy

The primary types of diabetic neuropathy are sensorimotor and autonomic (Table 1). A patient may have only one type of neuropathy or might develop different combinations of neuropathies.

Sensory neuropathies can be classified as distal symmetric polyneuropathy, focal neuropathy (e.g., diabetic mononeuropathy), and diabetic amyotrophy. Motor neuropathies are identified by the muscles that are involved. Autonomic neuropathies may be classified by the system that is affected (e.g., endocrine, gastrointestinal, genitourinary). Symptoms of neuropathy has precede the diabetes or early finding various forms of diabetic neuropathy are listed in Table 2.

Once a careful history and a thorough physical examination have established the presence of diabetic neuropathy (Table 3), assessment strategies can help in management.

Sensorimotor Neuropathy

In sensory nerve damage, the nerves with the longest axons usually are affected first, resulting in a stocking-and-glove distribution. Small fiber damage affects sensation of temperature, light touch, pinprick, and pain. Large fiber damage diminishes vibratory sensation, position sense, muscle strength, sharp-dull discrimination, and two-point discrimination. Polyradiculopathies and severe band-like abdominal pain also may occur.

Polyradiculopathy may be identified by electromyography or a sensory examination that shows altered sensation along the course of the nerve trunk. Bilateral thigh pain or weakness with atrophy of the iliopsoas, quadriceps, and adductor muscles also may be present. Physical findings involving the L2, L3, and L4 nerve roots or an abnormal electromyograph should alert the physician to the presence of polyradiculopathy.

When evaluating for sensorimotor neuropathy, it is important to ask the patient about recent falls and to look for loss of Achilles and patellar tendon reflexes, gait ataxia, and balance problems.


Distal symmetric polyneuropathy, the most common form of diabetic neuropathy, affects approximately 40 percent of patients who have had diabetes for 25 years or longer. Most often, this neuropathy develops in the feet. The course is chronic and progressive; in rare cases, however, the neuropathy resolves spontaneously in six to 12 months.

Distal symmetric polyneuropathy predisposes patients to variable pain, motor dysfunction, nerve palsies, ulcers, burns, infections, gangrene, and Charcot's disease. Affected patients also may develop neuropathic cachexia syndrome, which includes anorexia, depression, and weight loss. When testing is performed in patients with distal symmetric polyneuropathy and initial skin ulceration, almost 70 percent deny hypoesthesia, and about 50 percent can sense a cotton wisp and pinprick. (6)


Diabetic mononeuropathy has an acute onset and usually is asymmetric. Cranial, truncal, and peripheral nerves are involved. The neuropathy generally resolves spontaneously in three to 12 months, but in rare cases it may last for years.

Patients with diabetic mononeuropathy may develop visual changes or muscle weakness involving cranial nerves III, IV, and VI, as well as Bell's palsy. Cranial nerve III involvement results in ophthalmoplegia, ptosis, and diplopia with sparing of pupillary function. The median, radial, and lateral popliteal nerves are the most common sites of peripheral nerve involvement.

Occasionally, nerve palsies affect several unilateral nerves. When multiple nerves are involved, the term "mononeuropathy multiplex" is used. Vasculitis should be ruled out as a cause of the symptoms.


Diabetic amyotrophy, also known as femoral neuropathy or proximal motor neuropathy, usually is bilateral and frequently is associated with weight loss. This condition causes thigh muscle weakness, as well as variable pain and loss of the patellar reflex. Diabetic amyotrophy tends to occur more often in older male patients with type 2 diabetes.

Thigh muscle atrophy is prominent, disabling, and usually limited to the iliopsoas, quadriceps, and adductor muscles. Less often, the anterolateral calf muscles are involved. Recovery usually is spontaneous in six to 12 months, but amyotrophy may recur. Increasing circumferential thigh measurements may not indicate recovery because muscle can be replaced by fatty tissue.

Diabetic Autonomic Neuropathy

Diabetic autonomic neuropathy can develop in patients with type 1 or type 2 diabetes. Although autonomic neuropathy may occur at any stage of diabetes, (3,4) usually it develops in patients who have had the disease for 20 years or more with poor glycemic control. The reported prevalence of diabetic autonomic neuropathy varies widely, depending on the cohort studied and the methods of assessment. (7)

In autonomic disease, the sympathetic, parasympathetic, and enteric nerves are affected. Myelinated and unmyelinated nerve damage is found. Diabetic autonomic neuropathy may lead to hypoglycemic unawareness and increased pupillary latency. Many investigators have considered autonomic neuropathies to be irreversible. However, cardiac sympathetic dysinnervation has been shown to regress with tight glycemic control. (8)


The risk of cardiovascular events is at least two to four times higher in patients with diabetes. (9) Cardiovascular neuropathy is a result of damage to vagal and sympathetic nerves. Clinical findings may include exercise intolerance, persistent sinus tachycardia, no variation in heart rate during activities, and bradycardia. Baroreceptor disease contributes to supine hypertension.

In a patient with type 1 diabetes, an autonomic imbalance may result in a prolonged QT interval on the electrocardiogram (ECG), which may predispose the patient to life-threatening cardiac arrhythmias and sudden death. (7) Diabetic neuropathy also can reduce appreciation of ischemic pain, which may delay appropriate medical therapy and lead to death. (7)

Orthostatic blood pressure measurements may be used to evaluate cardiovascular autonomic dysfunction. (10) Stress testing should be considered before any patient with diabetes starts an exercise program.


Vasomotor neuropathy frequently causes orthostatic hypotension by affecting the splanchnic and peripheral vascular beds. Symptoms of syncope or dizziness often have day-to-day variability and may be exacerbated by insulin therapy or the postprandial state, in which there is splanchnic shunting of blood. The evaluation should include vital signs, an ECG, and orthostatic blood pressure measurements.

In diabetic neuropathy, neuronal input to the peripheral vasculature is decreased or absent. Resultant peripheral vasomotor instability can manifest as persistent excess peripheral circulation (hyperemia) and peripheral edema. Loss of sympathetic tone in the blood vessels results in maximal vasodilation, which can lead to arteriovenous shunting in the soft tissue and bone. Increased blood flow through the bone causes calcium to wash from the cortical stores. Defective bone homeostasis and bone demineralization may result. (11)

The occurrence of peripheral vasomotor instability and peripheral sudomotor neuropathy is termed "autosympathectomy." The patient with autosympathectomy has peripheral vasomotor reflexes similar to those in a nondiabetic patient after sympathectomy. The mechanism by which the body senses and responds to changes in blood pressure by reflex vasodilation or contraction of peripheral vessels is impaired. Autosympathectomy and distal symmetric polyneuropathy are considered necessary for the development of Charcot's disease (diabetic neuropathic arthropathy). (12)


Sudomotor neuropathy may cause hyperhidrosis and heat intolerance in the upper torso or anhidrosis in the lower extremities. Temperature elevation is rare, but sometimes occurs. The skin of the extremities may feel pruritic and may display thinning, hair loss, dryness, flaking, cracks, increased callus formation, and nail dystrophies. These skin changes increase the risk of ulceration.


Gastrointestinal autonomic neuropathy may cause paresis anywhere in the digestive tract, with damage to small myelinated and unmyelinated splanchnic nerves. Reduced contraction amplitudes of the tubular esophagus may cause mild dysphagia. Motility studies, such as scintigraphy after a radiolabeled meal, are helpful in the evaluation of nausea, vomiting, early satiety, and delayed gastric emptying.

Diabetic diarrhea is caused by increased or uncoordinated transit time in the small intestine, bacterial overgrowth, or increased intestinal secretion. (13) Stool cultures and flexible sigmoidoscopy may be helpful in excluding other causes of diarrhea, such as parasitic infection, colon cancer or polyps, celiac sprue, and inflammatory bowel disease.

Decreased transit time in the large intestine may cause constipation or impacted stool. Abdominal radiography or computed tomography may reveal megacolon or fecal impaction. Neuropathic fecal incontinence also may occur in patients with gastrointestinal autonomic neuropathy. A reduced threshold of conscious rectal sensation is manifested by a decreased resting anal sphincter pressure. (14)


In patients with diabetic bladder dysfunction, inability to sense a full bladder and detrusor muscle hypoactivity cause retention and incomplete voiding of urine. These conditions can progress to overflow incontinence and urinary tract infections. Hyperglycemia alone also can cause increased urine production and incontinence.

The evaluation of the patient with diabetes who has bladder dysfunction should begin with a review of medications. Drugs that impair detrusor contractility and increase urethral tone include calcium channel blockers, anticholinergics, alpha- and beta-adrenergic agonists, narcotics, antidepressants, and antipsychotics. Further work-up should include a patient's voiding record, post-void residual testing, and urinalysis. Cystometric and urodynamic studies confirm the diagnosis. (7)


Erectile dysfunction can occur at an early age in men with diabetes. (15) It develops in 35 percent of men with diabetes between 20 and 59 years of age and 65 percent of men with diabetes 60 years or older. (16) The primary cause is pelvic plexus neuropathy; a decrease in nitric oxide, which is required to initiate an erection, contributes to the condition.

Routine screening is important because erectile dysfunction may occur before the development of other autonomic signs. The evaluation of erectile dysfunction includes a sexual history, a genital examination, a serum testosterone level, and prolactin and thyrotropin levels.


In women, diabetic neuropathy may cause vaginal dryness, decreased perineal sensation, dyspareunia, reduced libido, or anorgasmy. (7) Routine screening should be performed because sexual dysfunction may precede other autonomic signs. A detailed sexual history, pelvic examination, and urinalysis help rule out other diagnoses.

Preventing Complications of Diabetic Neuropathy

Early detection and control of diabetes and coexisting risk factors for neuropathy (e.g., smoking, alcohol abuse, hypertension) can prevent, delay, or slow the progression of diabetic neuropathy. (2,5,17-19)


The Diabetes Control Complications Trial (DCCT) (17,20) demonstrated that tight glycemic control may result in a 60 percent reduction in the risk of developing clinical neuropathy. The American Diabetes Association (ADA) (19) has adopted the DCCT-established standards for tight glycemic control in patients with type 1 diabetes, 13 to 39 years of age at initiation of the study: a mean blood glucose level of 155 mg per dL (8.6 mmol per L) and a hemoglobin A1C value of 7.2 percent. (17,19,20) In patients with type 2 diabetes, the A1C value should be less than 7.0 percent, and peak postprandial plasma glucose levels should be less than 180 mg per dL (10.0 mmol per L). No clinical trial data are available on the effects of glycemic control in older patients, in young children, or in patients with advanced complications.

The American Association of Clinical Endocrinologists (21) recommends an A1C value of less than 6.5 percent in patients with type 1 or type 2 diabetes.

The rights holder did not grant the American Academy of Family Physicians the right to sublicense this material to a third party. For the missing item, see the original print version of this publication.


Daily foot care is essential for preventing complications of diabetic neuropathy (see patient information handout). Patients should be instructed to inspect their feet daily for dry or cracking skin, fissures, plantar callus formation, and signs of infection between the toes and around the toenails. (22,23) Application of topical ointments to intertriginous areas should be avoided. (11)

Properly fitted footwear is crucial. New shoes are a common cause of ulceration and should be broken in slowly. Patients also should avoid sources of possible trauma, such as walking barefoot, cutting nails incorrectly, and exposing their feet to hot objects or chemicals such as hydrogen peroxide, iodine, or astringents (e.g., witch hazel).

At each visit, the physician should examine the patient's feet visually to detect evidence of neuropathy or early lesions. The ADA (24) recommends a thorough annual foot examination by a health care professional for all patients with diabetes. The feet should be checked for skin breaks, red or callused areas, decreased or absent pedal pulses, and delayed capillary refilling, bony deformities, and protective sensation. Protective sensation is assessed by the 5.07 Semmes-Weinstein (10-g) nylon filament test (10-g monofilament test; Figure 1). (11,25)

Once a patient has diabetic neuropathy, foot care becomes essential for preventing ulceration, infection, and amputation. (26,27) A multidisciplinary team approach can reinforce preventive advice and help the patient develop and maintain good foot care habits.

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.


(1.) Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study [published correction appears in Neurology 1993;43:2345]. Neurology 1993;43:817-24.

(2.) Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:89-94.

(3.) Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001;24:1229-31.

(4.) Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001;24:1448-53.

(5.) Greene DA, Sima AF, Pfeifer MA, Albers JW. Diabetic neuropathy. Annu Rev Med 1990;41:303-17.

(6.) Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract 2001;54:115-28.

(7.) Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553-79.

(8.) Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 1999;48:92-101.

(9.) Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care 1998;21:1551-9.

(10.) May O, Arildsen H. Assessing cardiovascular autonomic neuropathy in diabetes mellitus: how many tests to use? J Diabetes Complications 2000;14:7-12.

(11.) Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kravette M, Kravitz S, et al. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg 2000;39(5 suppl):S1-60.

(12.) Sommer TC, Lee TH. Charcot foot: the diagnostic dilemma [published correction appears in Am Fam Physician 2002;65:2436-8]. Am Fam Physician 2001;64:1591-8.

(13.) Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993;68:691-702.

(14.) Wald A. Incontinence and anorectal dysfunction in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995;7:737-9.

(15.) Chu NV, Edelman SV. Erectile dysfunction and diabetes. Curr Diab Rep 2002;2:60-6.

(16.) Minhas S, Eardley I. Diabetes mellitus and impotence. In: Carson CC 3d, Kirby RS, Goldstein I, eds. Textbook of erectile dysfunction. Oxford, England: Isis Medical Media, 1999:541-50.

(17.) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.

(18.) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet 1999;354:602]. Lancet 1998;352:837-53.

(19.) American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4-36.

(20.) Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995;38:869-80.

(21.) American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management 2002 update. Endocrine Practice 2002;8(suppl 1):41-65.

(22.) Hollingshead TS. Pathophysiology and treatment of diabetic foot ulcer. Clin Podiatr Med Surg 1991;8:843-55.

(23.) Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diagnosis and classification. Am Fam Physician 1998;57:1325-32,1337-8.

(24.) Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM; American Diabetes Association. Preventive foot care in diabetes. Diabetes Care 2004;27(suppl 1):S63-4.

(25.) National Diabetes Education Program. Feet can last a lifetime. Screening form for diabetes foot disease. Accessed online February 13, 2005, at:

(26.) Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician 2002;66:1655-62.

(27.) Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S65-7.

ANN M. ARING, M.D., is assistant program director for the family practice residency program at Riverside Methodist Hospital, Columbus, Ohio, and clinical assistant professor in the Department of Family Medicine at Ohio State University College of Medicine and Public Health, Columbus. Dr. Aring graduated from Ohio State University College of Medicine and Public Health and completed family practice residency at Riverside Methodist Hospital.

DAVID E. JONES, M.D., D.P.M., is a podiatrist in Columbus, Ohio. He is a graduate of the Ohio College of Podiatric Medicine, Cleveland, and the Universidad International de Las Americas School of Medicine, San Jose, Costa Rica. Dr. Jones completed podiatry residency at Northern General Hospital for Joint Diseases, New York, N.Y.

JAMES M. FALKO, M.D., is professor emeritus of medicine in the Division of Endocrinology, Diabetes and Metabolism at Ohio State University College of Medicine and Public Health. Dr. Falko also is director of academic affairs, internal medicine, at Riverside Methodist Hospital.

Address correspondence to Ann M. Aring, M.D., Riverside Family Practice, 697 Thomas Ln., Columbus, OH 43214 (e-mail: Reprints are not available from the authors.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Diabetic neuropathy
Home Contact Resources Exchange Links ebay